Citigroup Forecasts Strong Price Appreciation for Fortrea (NASDAQ:FTRE) Stock

Key Points

• Citigroup raised Fortrea’s price target to $27 from $22 and maintained a “buy” rating, implying approximately 26.8% upside from the reported $21.29 share price.
• Fortrea exceeded third-quarter expectations, reporting adjusted EPS of $0.28 versus $0.22 expected and revenue of $691.5 million versus $671.6 million; management also raised its adjusted EBITDA outlook for 2026.
• Despite the earnings beat, shares fell 8% in Friday trading. Analyst sentiment remains mixed, with a consensus “hold” rating and average price target of $23.68, while the company continues to post a negative net margin.

Fortrea (NASDAQ:FTRE - Get Free Report) had its target price increased by Citigroup from $22.00 to $27.00 in a report released on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's target price would suggest a potential upside of 26.82% from the company's current price.

FTRE has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft upgraded Fortrea from a "hold" rating to a "buy" rating and boosted their price objective for the company from $20.00 to $25.00 in a report on Thursday, October 15th. Zacks Research lowered Fortrea from a "hold" rating to a "strong sell" rating in a research note on Monday, October 12th. Wall Street Zen upgraded Fortrea from a "hold" rating to a "buy" rating in a research report on Saturday, October 10th. Robert W. Baird set a $23.00 target price on shares of Fortrea in a research note on Thursday, July 30th. Finally, TD Cowen upped their price target on shares of Fortrea from $19.00 to $23.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $23.68.

Fortrea Trading Down 8.0%

NASDAQ:FTRE traded down $1.85 during mid-day trading on Friday, hitting $21.29. 2,873,286 shares of the stock traded hands, compared to its average volume of 1,562,137. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -23.40, a PEG ratio of 0.62 and a beta of 1.93. Fortrea has a 52 week low of $8.55 and a 52 week high of $26.16. The firm's 50 day moving average is $20.22 and its two-hundred day moving average is $15.73. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 1.98.

Fortrea (NASDAQ:FTRE - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.06. Fortrea had a negative net margin of 3.18% and a positive return on equity of 10.72%. The business had revenue of $691.50 million during the quarter, compared to the consensus estimate of $671.57 million. On average, equities research analysts predict that Fortrea will post 0.86 earnings per share for the current year.

Insider Activity

In other news, CEO Anshul Thakral sold 99,869 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the transaction, the chief executive officer owned 316,797 shares in the company, valued at approximately $6,069,830.52. This trade represents a 23.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.73% of the company's stock.

Institutional Trading of Fortrea

Several institutional investors and hedge funds have recently made changes to their positions in the company. Financial Management Professionals Inc. bought a new stake in shares of Fortrea in the 3rd quarter valued at about $30,000. Ancora Advisors LLC purchased a new position in Fortrea during the second quarter valued at approximately $59,000. Allworth Financial LP increased its holdings in Fortrea by 22.3% during the second quarter. Allworth Financial LP now owns 3,923 shares of the company's stock valued at $68,000 after buying an additional 716 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Fortrea in the third quarter worth approximately $97,000. Finally, Public Employees Retirement System of Ohio bought a new position in Fortrea in the second quarter worth approximately $115,000.

Key Fortrea News

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, above the $0.22 consensus estimate and up from $0.12 a year earlier. Revenue of $691.5 million also exceeded expectations of $671.6 million. Fortrea Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management forecast 2026 revenue of $2.665 billion to $2.690 billion and raised its adjusted EBITDA outlook to $210 million-$218 million, signaling improved expected operating profitability. Fortrea Raises Adjusted EBITDA Outlook
• Positive Sentiment: Barclays raised its price target from $23 to $26 and maintained an “overweight” rating, reflecting increased confidence in Fortrea’s valuation and earnings potential. Barclays Fortrea Rating
• Neutral Sentiment: Despite the earnings beat, Fortrea continues to report a negative net margin, so investors may remain focused on whether the improved EBITDA outlook translates into sustainable bottom-line earnings. Fortrea Third-Quarter Results
• Negative Sentiment: Fortrea shares fell after the results, indicating that investors may have viewed the revised guidance, business outlook, or earnings quality as less compelling than the headline quarterly beat. Fortrea Shares Drop After Q3 Results

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.